FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
In combination, tesamorelin and ipamorelin represent a dual-pathway approach to modulating endogenous GH pulsatility, leveraging established physiological interactions between GHRH and ghrelin signaling.
While direct combination studies are limited, existing mechanistic and translational evidence supports further investigation of this pairing as a research model for coordinated GH axis regulation.
Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) composed of 44 amino acids, designed to stimulate endogenous, pulsatile growth hormone (GH) secretion from the anterior pituitary [1].
By binding to the GHRH receptor, tesamorelin activates cAMP-mediated signaling in somatotroph cells, promoting downstream increases in insulin-like growth factor-1 (IGF-1) while preserving normal feedback regulation [2].
Tesamorelin is a well-characterized tool for elucidating GHRH-driven regulation as both model organisms and clinical research have investigated for effects on [3]:
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively activates the ghrelin (GHS-R1a) receptor in the hypothalamus and pituitary [4].
Through this pathway, ipamorelin stimulates pulsatile growth hormone (GH) release without significantly increasing other pituitary hormones such as cortisol or prolactin.
In research settings, ipamorelin has been investigated for its high signaling specificity and favorable endocrine selectivity, making it a complementary agent to GHRH analogs when studying coordinated regulation of endogenous GH secretion.
The rationale for combining tesamorelin and ipamorelin is grounded in well-characterized physiological cross-talk between the GHRH and ghrelin/GHS signaling systems, which regulate the amplitude and timing of endogenous growth hormone (GH) pulses.
Rather than acting redundantly, these peptides engage distinct but convergent control pathways within the somatotropic axis.
Tesamorelin is a GHRH analog that activates the GHRH receptor on pituitary somatotrophs, while Ipamorelin is a selective ghrelin (GHS-R1a) receptor agonist.
GHS-R1a activation is typically associated with PLC-linked signaling, intracellular calcium mobilization, and enhanced somatotroph responsiveness [5].
Importantly, ghrelin/GHS signaling does not independently raise cAMP, but it can potentiate GHRH-driven cAMP responses when both receptors are engaged.
Direct clinical trials specifically evaluating tesamorelin combined with ipamorelin are limited. However, the broader literature provides several relevant lines of evidence:
Taken together, this data supports the potential of tesamorelin–ipamorelin synergy via coordinated engagement of complementary regulatory pathways, even though formal combination trials remain sparse.
From a research-design perspective, allocating a greater proportion of the total peptide mass to tesamorelin (7 mg) can be viewed as emphasizing primary drivers through the main GHRH pathway, which establishes pulse timing and baseline GH output.
Ipamorelin (3 mg) can then function as a selective amplifier, enhancing somatotroph responsiveness through GHS-R1a–mediated cross-talk without broadly activating appetite or stress-related endocrine pathways. This lower ghrelin receptor agonist to GHRH ratio is in agreement with the literature in terms of producing synergistic GH secretion effects [6].
Beyond this high-level rationale, optimal dosing ratios are not established in the open literature and should be regarded as empirical parameters rather than evidence-based standards.
References:
2 Halmos, G., Szabo, Z., Dobos, N., Juhasz, E. and Schally, A. V. (2025) Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev. Endocr. Metab. Disord., Springer Science and Business Media LLC 26, 343–352
3 Results from the 26-week Confirmatory, Phase 3 Trial of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Excess Abdominal Fat: A Multicenter, Double-blind, Placebo-controlled Study with 404 Randomized Patients https://www.natap.org/2008/IAS/IAS_56.htm
4 Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., et al. (2020) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl. Androl. Urol., AME Publishing Company 9, S149–S159
5 Mear, Y., Enjalbert, A. and Thirion, S. (2013) GHS-R1a constitutive activity and its physiological relevance. Front. Neurosci., Frontiers Media SA 7, 87
6 Hataya, Y., Akamizu, T., Takaya, K., Kanamoto, N., Ariyasu, H., Saijo, M., et al. (2001) A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J. Clin. Endocrinol. Metab., The Endocrine Society 86, 4552
7 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582
8 Casanueva, F. F. and Dieguez, C. (1999) Growth hormone secretagogues: Physiological role and clinical utility. Trends Endocrinol. Metab., Elsevier BV 10, 30–38
9 Stanley, T. L., Chen, C. Y., Branch, K. L., Makimura, H. and Grinspoon, S. K. (2011) Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab., The Endocrine Society 96, 150–158
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Tesamorelin + Ipamorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
